Drug Type Small molecule drug |
Synonyms PSB 172656, PSB172656 |
Target |
Action antagonists |
Mechanism MRGPRX2 antagonists(MAS related GPR family member X2 antagonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Molecular FormulaC15H15F2N3O |
InChIKeyRHWXSISNXGMNNQ-UHFFFAOYSA-N |
CAS Registry2641397-91-1 |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Hypersensitivity | Preclinical | Belgium | 21 Apr 2025 | |
| Hypersensitivity | Preclinical | Germany | 21 Apr 2025 | |
| Inflammation | Preclinical | Belgium | 21 Apr 2025 | |
| Inflammation | Preclinical | Germany | 21 Apr 2025 |





